Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
ATF4 Antibody (SD20-92), Novus Biologicals™

Rabbit Monoclonal Antibody
Supplier: Novus Biologicals NBP267766
Description
ATF4 Monoclonal specifically detects ATF4 in Human, Mouse, Rat samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin.Specifications
ATF4 | |
Monoclonal | |
1 mg/mL | |
Western Blot 1:100-1:2000, Flow Cytometry 1:50-1:100, Immunohistochemistry 1:10 - 1:500, Immunocytochemistry/Immunofluorescence 1:10 - 1:500, Immunoprecipitation 1:10 - 1:500, Immunohistochemistry-Paraffin 1:50-1:200 | |
Activating transcription factor 4, activating transcription factor 4 (tax-responsive enhancer element B67), cAMP-dependent transcription factor ATF-4, cAMP-responsive element-binding protein 2, CREB-2DNA-binding protein TAXREB67, cyclic AMP-dependent transcription factor ATF-4, Cyclic AMP-responsive element-binding protein 2, TaxREB67, TAXREB67CREB2cAMP response element-binding protein 2, Tax-responsive enhancer element-binding protein 67, TXREB | |
Rabbit | |
Protein A purified | |
Lipid and Metabolism, Phospho Specific, Unfolded Protein Response, Unfolded Protein Response (UPR) | |
468 | |
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. | |
IgG |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation | |
SD20-92 | |
Unconjugated | |
TBS (pH7.4), 0.05% BSA, 40% Glycerol with 0.05% Sodium Azide | |
ATF4 | |
Recombinant protein within Human ATF4 aa 1-220/ 351. (SwissProt: P18848 Human; SwissProt: Q06507 Mouse; SwissProt: Q9ES19 Rat) | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction